Average time to pay
50 days
Register median: 31 days
Supplier payment record · 02487574
Reported period: –
View the government filing50 days
Register median: 31 days
21%
Register median: 14%
0 to 90 days
Declared in this filing
These are company-wide, self-reported figures—not a prediction for your invoice. Comparisons use the latest filings of 1,496 companies declaring construction contracts.
Already waiting for payment?
Use your amount and dates to estimate late-payment interest and fixed compensation.
15 filings
Late payments down 1 percentage pointsCompared with the previous filing
| Period ending | Days to pay | Paid late | Within 30 days | Over 60 days |
|---|---|---|---|---|
| 30 June 2026 | 50 | 21% | 36% | 37% |
| 31 December 2025 | 45 | 22% | 38% | 29% |
| 30 June 2025 | 50 | 22% | 35% | 31% |
| 31 December 2023 | 42 | 27% | 41% | 22% |
| 30 June 2023 | 42 | 27% | 41% | 21% |
| 31 December 2022 | 40 | 24% | 43% | 20% |
The preferred BMS terms for 3rd party vendors are default to 90 days. Payment terms are outlined in contracts with suppliers. Where a contract is not negotiated, the payment terms will be clearly stated on the Purchase Orders (POs) sent to suppliers. Any changes to the payment terms would require a contract amendment. For Health Care Professionals the standard payment terms are immediate, therefore meeting these terms are difficult to achieve when we consider time to send the invoice, process, approve and release for payment, currently 73% of the above reported late payments are due to Imme…
NA
No retention clauses were declared in this filing.
Bristol-Myers Squibb Pharmaceuticals Ltd reported an average of 50 days to pay an invoice for 1 January 2026 to 30 June 2026, with 36% of invoices paid within 30 days and 37% taking longer than 60 days. The official 2025 figure for large construction businesses is 33 days.
By its own filing, 21% of Bristol-Myers Squibb Pharmaceuticals Ltd's invoices were paid later than the agreed terms, against 14% across large construction businesses in 2025 and a median of 14% among the 1,496 companies on this register that declare construction contracts. That is down 1 points on its previous filing (22% for the period to 31 December 2025).
Bristol-Myers Squibb Pharmaceuticals Ltd declares no retention clauses in its construction contracts in this filing. Your subcontract governs; if it holds retention, the contract terms decide when it is released.
Yes, under the Late Payment of Commercial Debts (Interest) Act 1998, from the day after the final date for payment, at 8% over the Bank of England base rate plus a fixed sum per invoice, without any clause in the contract. The calculator works it out for your figures.